MET通路作为一个治疗靶点。
MET pathway as a therapeutic target.
作者信息
Kim Eric S, Salgia Ravi
机构信息
Section of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA.
出版信息
J Thorac Oncol. 2009 Apr;4(4):444-7. doi: 10.1097/JTO.0b013e31819d6f91.
Abstract
Dysregulation of mesenchymal-epithelial transition factor receptor tyrosine kinase pathway leads to cell proliferation, protection from apoptosis, angiogenesis, invasion, and metastasis. It can be dysregulated through overexpression, constitutive activation, gene amplification, ligand-dependent activation or mutation. New drugs targeting various mesenchymal-epithelial transition factor pathways are being investigated with promising results.
摘要
间充质-上皮转化因子受体酪氨酸激酶通路的失调会导致细胞增殖、抗凋亡、血管生成、侵袭和转移。它可通过过表达、组成性激活、基因扩增、配体依赖性激活或突变而失调。目前正在研究针对各种间充质-上皮转化因子通路的新药，且取得了有前景的结果。
相似文献
1
MET pathway as a therapeutic target.MET通路作为一个治疗靶点。
J Thorac Oncol. 2009 Apr;4(4):444-7. doi: 10.1097/JTO.0b013e31819d6f91.
2
Inhibition of HGF/MET as therapy for malignancy.抑制HGF/MET作为恶性肿瘤的治疗方法。
Expert Opin Ther Targets. 2009 May;13(5):569-81. doi: 10.1517/14728220902853917.
3
RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival.RNA干扰显示，肿瘤细胞信号传导和存活需要不依赖配体的Met活性。
Cancer Res. 2004 Nov 1;64(21):7962-70. doi: 10.1158/0008-5472.CAN-04-1043.
4
Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.携带MET基因扩增的肺癌细胞系在生长和存活方面依赖于Met。
Cancer Res. 2007 Mar 1;67(5):2081-8. doi: 10.1158/0008-5472.CAN-06-3495.
5
The function, proteolytic processing, and histopathology of Met in cancer.Met在癌症中的功能、蛋白水解加工及组织病理学
Adv Cancer Res. 2009;103:1-23. doi: 10.1016/S0065-230X(09)03001-2.
6
MET receptor tyrosine kinase as a therapeutic anticancer target.作为治疗性抗癌靶点的MET受体酪氨酸激酶
Cancer Lett. 2009 Jul 18;280(1):1-14. doi: 10.1016/j.canlet.2008.10.045. Epub 2008 Dec 18.
7
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.将MET作为克服与串扰相关的对EGFR抑制剂耐药性的一种策略。
Lancet Oncol. 2009 Jul;10(7):709-17. doi: 10.1016/S1470-2045(09)70137-8.
8
Redundant roles for Met docking site tyrosines and the Gab1 pleckstrin homology domain in InlB-mediated entry of Listeria monocytogenes.在内化素B介导的单核细胞增生李斯特菌进入过程中，甲硫氨酸对接位点酪氨酸和Gab1普列克底物蛋白同源结构域的多余作用
Infect Immun. 2005 Apr;73(4):2061-74. doi: 10.1128/IAI.73.4.2061-2074.2005.
9
Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors.携带MET基因扩增的癌细胞会激活替代信号通路以逃避MET抑制，但对Hsp90抑制剂仍敏感。
Cell Cycle. 2009 Jul 1;8(13):2050-6. doi: 10.4161/cc.8.13.8861. Epub 2009 Jul 27.
10
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.MET受体酪氨酸激酶是头颈部鳞状细胞癌潜在的新型治疗靶点。
Cancer Res. 2009 Apr 1;69(7):3021-31. doi: 10.1158/0008-5472.CAN-08-2881. Epub 2009 Mar 24.
引用本文的文献
1
Fuelling the Fight from the Gut: Short-Chain Fatty Acids and Dexamethasone Synergise to Suppress Gastric Cancer Cells.从肠道助力抗癌：短链脂肪酸与地塞米松协同抑制胃癌细胞
Cancers (Basel). 2025 Jul 28;17(15):2486. doi: 10.3390/cancers17152486.
2
Gastrointestinal health and nutritional strategies in autism spectrum disorder.自闭症谱系障碍中的胃肠道健康与营养策略
J Gastroenterol. 2025 Jun 18. doi: 10.1007/s00535-025-02269-1.
3
Targeted therapies in hepatocellular carcinoma: past, present, and future.肝细胞癌的靶向治疗：过去、现在与未来
Front Oncol. 2024 Aug 29;14:1432423. doi: 10.3389/fonc.2024.1432423. eCollection 2024.
4
Oncogenic alterations in advanced NSCLC: a molecular super-highway.晚期非小细胞肺癌中的致癌改变：一条分子高速公路。
Biomark Res. 2024 Feb 12;12(1):24. doi: 10.1186/s40364-024-00566-0.
5
MiRNA-related metastasis in oral cancer: moving and shaking.口腔癌中与微小RNA相关的转移：动态变化
Cancer Cell Int. 2023 Aug 27;23(1):182. doi: 10.1186/s12935-023-03022-5.
6
Recent advances in non-small cell lung cancer targeted therapy; an update review.非小细胞肺癌靶向治疗的最新进展；综述更新
Cancer Cell Int. 2023 Aug 11;23(1):162. doi: 10.1186/s12935-023-02990-y.
7
Multi-Omics Identification of Genetic Alterations in Head and Neck Squamous Cell Carcinoma and Therapeutic Efficacy of HNC018 as a Novel Multi-Target Agent for c-MET/STAT3/AKT Signaling Axis.多组学鉴定头颈部鳞状细胞癌中的遗传改变和 HNC018 作为新型 c-MET/STAT3/AKT 信号轴多靶点药物的治疗效果。
Int J Mol Sci. 2023 Jun 16;24(12):10247. doi: 10.3390/ijms241210247.
8
Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer.晚期非小细胞肺癌的新兴靶向治疗
Cancers (Basel). 2023 May 24;15(11):2899. doi: 10.3390/cancers15112899.
9
ETS-1/c-Met drives resistance to sorafenib in hepatocellular carcinoma.ETS-1/c-Met驱动肝癌对索拉非尼产生耐药性。
Am J Transl Res. 2023 Feb 15;15(2):896-913. eCollection 2023.
10
Major Molecular Signaling Pathways in Oral Cancer Associated With Therapeutic Resistance.与治疗耐药相关的口腔癌主要分子信号通路
Front Oral Health. 2021 Jan 25;1:603160. doi: 10.3389/froh.2020.603160. eCollection 2020.
本文引用的文献
1
Review of clinic trials: agents targeting c-Met.临床试验综述：靶向c-Met的药物
Rev Recent Clin Trials. 2007 May;2(2):143-7. doi: 10.2174/157488707780599357.
2
Molecular cancer therapy: can our expectation be MET?分子癌症治疗：我们的期望能够实现吗？
Eur J Cancer. 2008 Mar;44(5):641-51. doi: 10.1016/j.ejca.2008.01.022. Epub 2008 Mar 4.
3
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.桩蛋白是肺癌体细胞突变的一个靶点：对细胞生长和侵袭的影响。
Cancer Res. 2008 Jan 1;68(1):132-42. doi: 10.1158/0008-5472.CAN-07-1998.
4
Experimental validation of miRNA targets.微小RNA（miRNA）靶标的实验验证
Methods. 2008 Jan;44(1):47-54. doi: 10.1016/j.ymeth.2007.09.005.
5
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.在对吉非替尼或厄洛替尼产生获得性耐药的表皮生长因子受体（EGFR）突变型肺肿瘤中，MET扩增可伴有或不伴有T790M突变。
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7. doi: 10.1073/pnas.0710370104. Epub 2007 Dec 18.
6
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.PF-2341066（一种间变性淋巴瘤激酶和c-Met的新型抑制剂）在间变性大细胞淋巴瘤实验模型中的减瘤抗肿瘤活性。
Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22. doi: 10.1158/1535-7163.MCT-07-0365.
7
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts.AMG 102是一种完全人源化的抗肝细胞生长因子/分散因子中和抗体，可增强替莫唑胺或多西他赛对U - 87 MG细胞及异种移植瘤的疗效。
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6735-42. doi: 10.1158/1078-0432.CCR-06-2969.
8
miRNA: the new gene silencer.微小RNA：新型基因沉默因子
Am J Clin Pathol. 2007 Nov;128(5):830-6. doi: 10.1309/2JK279BU2G743MWJ.
9
Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion.小细胞肺癌中c-MET/HGF信号通路的下游信号传导及特异性抑制：对肿瘤侵袭的影响
Br J Cancer. 2007 Aug 6;97(3):368-77. doi: 10.1038/sj.bjc.6603884. Epub 2007 Jul 31.
10
The MET receptor tyrosine kinase in invasion and metastasis.MET受体酪氨酸激酶在侵袭和转移中的作用
J Cell Physiol. 2007 Nov;213(2):316-25. doi: 10.1002/jcp.21183.
Zotero 插件